US 11,905,336 B2
Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
Dale Christensen, Austin, TX (US); and John J. Koleng, Austin, TX (US)
Assigned to Lung Therapeutics, Inc., Austin, TX (US)
Appl. No. 17/274,721
Filed by Lung Therapeutics, Inc., Austin, TX (US)
PCT Filed Sep. 10, 2019, PCT No. PCT/US2019/050332
§ 371(c)(1), (2) Date Mar. 9, 2021,
PCT Pub. No. WO2020/055812, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/728,997, filed on Sep. 10, 2018.
Prior Publication US 2021/0347820 A1, Nov. 11, 2021
Int. Cl. A61K 45/06 (2006.01); C07K 7/08 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01); C07K 7/06 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 45/06 (2013.01); C07K 7/08 (2013.01); C07K 14/705 (2013.01); A61K 38/00 (2013.01); C07K 2319/10 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A peptide comprising aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 7) or Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8), wherein: “a” in SEQ ID NO: 7 or SEQ ID NO: 8 is D-alanine; wherein either amino acid sequence may optionally comprise at least one non-standard amino acid substitution; and the peptide is soluble in aqueous solution.